drug_type
RELEVANT_DRUG
intervention_type
Biological (monoclonal antibody)
drug_description
Human IgG1κ anti-CD38 monoclonal antibody (brand name Darzalex) given intravenously; binds CD38 on leukemic cells to induce ADCC, CDC, ADCP, and apoptosis, and inhibits CD38 ectoenzyme (NADase) activity to reduce adenosine-mediated immunosuppression.
nci_thesaurus_concept_id
C74007
nci_thesaurus_preferred_term
Daratumumab
nci_thesaurus_definition
A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon administration, daratumumab targets and binds to CD38 expressed on tumor cells. This triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab depletes CD38-expressing immunosuppressive regulatory T- and B-cells and myeloid-derived suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.
drug_mesh_term
daratumumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Human IgG1-kappa anti-CD38 monoclonal antibody that binds CD38 on tumor cells to induce antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis; also depletes CD38+ immunosuppressive cells and inhibits CD38 ectoenzyme (NADase) activity to reduce adenosine-mediated immunosuppression.
drug_name
Daratumumab
nct_id_drug_ref
NCT07021677